MedTrace Logo

Buspirone as a Potential Treatment for Recurrent Central Apnea

NCT00746954 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2016-03-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether buspirone compared to acetazolamide and to placebo will reduce the number and/or severity of breathing pauses during sleep that occur in some patients with Heart Failure.

Conditions

Interventions

DRUG

Acetazolamide

Cabonic Anhydrase inhibitor

DRUG

Buspirone

Agonist of a 5-HT1a receptor with some D2 agonist properties.

Sponsors & Collaborators

  • University Hospitals Cleveland Medical Center

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Kingman P. Strohl, MD · VA Medical Center-Cleveland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00746954 on ClinicalTrials.gov